The circulating tumor cells (CTC) and the AR splice variant 7 (AR-V7) have been proposed as prognostic and predictive biomarkers in patients with mCRPC treated with abiraterone acetate and enzalutamide [34,35]. The gene discussed is AR; the disease is neoplasm.